亚太药业(002370.SZ)发布前三季度业绩，归母净利润9719.5万元，同比增长2909.49%

Core Insights - The company reported a revenue of 228 million yuan for the first three quarters of 2025, representing a year-on-year decline of 25.59% [1] - The net profit attributable to shareholders reached 97.195 million yuan, showing a significant year-on-year increase of 2909.49% [1] - The net loss attributable to shareholders, after excluding non-recurring gains and losses, amounted to 56.5853 million yuan [1] Financial Performance - Revenue for the first three quarters: 228 million yuan, down 25.59% year-on-year [1] - Net profit attributable to shareholders: 97.195 million yuan, up 2909.49% year-on-year [1] - Net loss attributable to shareholders (excluding non-recurring items): 56.5853 million yuan [1]